Small-Fiber-Neuropathie: Schmerzlinderung dank Immunglobulintherapie?

2021 ◽  
Vol 04 (04) ◽  
pp. 306-307
Keyword(s):  
2006 ◽  
Vol 37 (5) ◽  
pp. 38
Author(s):  
JANE SALODOF MACNEIL

2007 ◽  
Vol 35 (7) ◽  
pp. 39
Author(s):  
CHRISTINE KILGORE
Keyword(s):  

2004 ◽  
Vol 31 (S 1) ◽  
Author(s):  
Z Katsarava ◽  
Ö Yaldizli ◽  
C Voulkoudis ◽  
S Esser ◽  
HC Diener ◽  
...  

2021 ◽  
Vol 14 ◽  
pp. 175628642110043
Author(s):  
Nadine Egenolf ◽  
Caren Meyer zu Altenschildesche ◽  
Luisa Kreß ◽  
Katja Eggermann ◽  
Barbara Namer ◽  
...  

Background and aims: Small fiber neuropathy (SFN) is increasingly suspected in patients with pain of uncertain origin, and making the diagnosis remains a challenge lacking a diagnostic gold standard. Methods: In this case–control study, we prospectively recruited 86 patients with a medical history and clinical phenotype suggestive of SFN. Patients underwent neurological examination, quantitative sensory testing (QST), and distal and proximal skin punch biopsy, and were tested for pain-associated gene loci. Fifty-five of these patients additionally underwent pain-related evoked potentials (PREP), corneal confocal microscopy (CCM), and a quantitative sudomotor axon reflex test (QSART). Results: Abnormal distal intraepidermal nerve fiber density (IENFD) (60/86, 70%) and neurological examination (53/86, 62%) most frequently reflected small fiber disease. Adding CCM and/or PREP further increased the number of patients with small fiber impairment to 47/55 (85%). Genetic testing revealed potentially pathogenic gene variants in 14/86 (16%) index patients. QST, QSART, and proximal IENFD were of lower impact. Conclusion: We propose to diagnose SFN primarily based on the results of neurological examination and distal IENFD, with more detailed phenotyping in specialized centers.


Sign in / Sign up

Export Citation Format

Share Document